Volume 8, Issue 4 (2-1995)                   Med J Islam Repub Iran 1995 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
AFRASIABI M, ZOLNOORIAN Z, JAVADPOOR S H. PHARMA COKINETICS OF RECOMBINANT ERYTHROPOIETIN AND RED CELL METABOLISM IN HAEMODIALYSIS PATIENTS. Med J Islam Repub Iran 1995; 8 (4) :229-231
URL: http://mjiri.iums.ac.ir/article-1-1361-en.html
PHARMA COKINETICS OF RECOMBINANT ERYTHROPOIETIN AND RED CELL METABOLISM IN HAEMODIALYSIS PATIENTS
MORTEZA AFRASIABI , ZAHRA ZOLNOORIAN , SEYYED HOSSEIN JAVADPOOR
From the Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, The Coombe Hospital, Dublin
Abstract:   (4451 Views)
The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of the sustained increase in haemoglobin neither the red ce1l2,3,-diphosphoglycerate (2,3- DPO) nor the P50 decreased from the pretreatment values. The mechanism which governs the rise in 2,3-diphosphoglycerate in chronic renal failure is different from the adaptive mechanism which operates in other types of anaemia.
Keywords: Recombinant Erythropoietin. Red Cell Metabolism, Chronic Renal Failure
Full-Text [PDF 376 kb]   (1494 Downloads)    
Type of Study: Original Research | Subject: Gynecology & Obstetrics
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.